⏱ 1 Year55D5 score
BUYGILD
Entry$156.40
Live$157.19
Today▲ +2.19%
Since pick▲ +0.51%
+2% vs analyst target · new source · 1 agree · 0 dissent
Why BUY: Jefferies lifts Gilead to $185 (Buy) after its $1.275B deal for an oral IL-23 drug; shares are up 30% this year.
⚠ It trades ~2% under its 52-week high, and Oct 29 earnings could reset expectations either way.